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Abstract
Background:  Patients with metastatic breast cancer (MBC) are frequently exposed to high
cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. This phase II trial
evaluated the efficacy and toxicity of docetaxel plus cisplatin, as salvage chemotherapy in patients
with MBC resistant to prior anthracyclines.
Methods: Patients with MBC that had progressed after at least one prior chemotherapy regimen
containing anthracyclines received docetaxel 75 mg/m2 followed by cisplatin 60 mg/m2 every 3
weeks for a maximum of 6 cycles or until disease progression.
Results: Between Jan 2000 and May 2002, 24 patients with tumors primary resistant and 15 with
secondary resistant disease were accrued. All 39 patients were evaluable for safety and 36 for
efficacy. The objective response rate was 31% (95% CI, 16–45%) with 3 complete responses. The
median time to disease progression was 7 months, and the median overall survival was 23 months
(median follow-up of 41 months). Neutropenia was the most frequently observed severe
hematologic toxicity (39% of patients), whereas asthenia and nausea were the most common non-
hematologic toxicities. No treatment-related death was observed.
Conclusion:  In conclusion, we found docetaxel plus cisplatin to be an active and safe
chemotherapy regimen for patients with MBC resistant to anthracyclines.
Background
In the management of breast cancer, anthracycline-based
chemotherapy regimens remain standard adjuvant or
first-line palliative treatment. Furthermore, some patients
cannot be treated with anthracyclines due to impaired car-
diac function. It is thus important to identify active, well-
tolerated, not anthracycline cross-resistant, salvage regi-
mens [1].
Taxanes (docetaxel and paclitaxel) are currently the most
extensively studied new chemotherapeutic agents for met-
astatic breast cancer (MBC). Single-agent docetaxel has
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demonstrated significant survival advantages over other
recognized regimens in 2 large randomized trials in
patients with anthracycline-pretreated MBC [2,3]. Phase II
data suggest that docetaxel is the most active agent yet
available for the treatment of MBC [4]. Docetaxel also has
some activity in paclitaxel-resistant MBC [5].
Cisplatin monotherapy has shown response rate of 9% in
salvage settings, and 50% as first-line therapy [6]. Because
docetaxel and cisplatin are both active and have different
mechanisms of action, this combination may provide
additive effect against MBC. Although docetaxel and cispl-
atin were not actively synergistic in preclinical studies
[7,8], this combination chemotherapy has been widely
used for treatment of a variety of tumor types [9-13]. Prior
phase I studies showed the feasibility of this combination
and its activity on different tumors [14]. Considering the
single-agent activity of both drugs, their different mecha-
nism of action and distinct toxicity profile, we designed
this phase II study, in which the combination was evalu-
ated as a salvage therapy in patients with anthracycline-
resistant MBC.
Methods
Eligibility
Eligible patients had measurable or assessable histologi-
cally confirmed breast cancer that had progressed after at
least one prior chemotherapy regimen containing anthra-
cyclines. All patients had Eastern Cooperative Oncology
Group performance status of 2 or lower and adequate
bone marrow, hepatic, and renal function, defined as
white blood cells ≥4000/µL, absolute neutrophil count
≥1500/µL, platelets ≥100,000/µL, total bilirubin ≤2.0 mg/
dL, transaminases ≤3 times the upper normal limit, and
serum creatinine ≤1.5 mg/dL. Concurrent radiation or
hormonal therapy was not allowed; however, patients
with clinically stable metastases of the brain or other sites
who had completed radiation therapy were permitted.
Patients were eligible regardless of the nature of prior ther-
apy, including high-dose therapy with stem cell support
and prior exposure to paclitaxel. Any prior antitumor
treatment had been completed at least 1 month before
entering this study. Patients were excluded if they had
severe comorbid illness, symptomatic peripheral neurop-
athy of any origin, or a history of anaphylaxis of any type.
All patients were provided a thorough explanation of the
study, and they signed informed consent prior to enroll-
ment into the study.
Definition of anthracycline-resistance
Patients were classified as primary and secondary anthra-
cycline-resistant. Primary anthracycline-resistance was
defined as relapse during or within 12 months after
anthracycline-based adjuvant therapy, or disease progres-
sion with no intervening response during anthracycline-
containing chemotherapy for MBC. Secondary resistance
was defined as relapse more than 12 months after receiv-
ing adjuvant anthracycline chemotherapy, or disease pro-
gression at some time after a documented clinical
response to anthracycline-based chemotherapy for MBC.
Pretreatment and follow-up evaluation
Pretreatment evaluation included a complete medical his-
tory and physical examination, a computed tomographic
(CT) scan of the chest and abdomen, magnetic resonance
imaging (MRI) of the brain, and a bone scintigraphy to
assess the extent of disease. Follow-up consisted of physi-
cal examination, monitoring of toxic effects, a complete
blood count, liver function tests, chest radiography, and
CT scan as clinically indicated.
Tumor response and toxicity were recorded in accordance
with the World Health Organization (WHO) criteria.
Responses were assessed every 2 cycles of chemotherapy,
and patients were evaluated before each new treatment
cycle for toxicities.
Treatment plan
The treatment consisted of docetaxel (Taxotere®, Aventis,
Bridgewater, NJ) 75 mg/m2 given by a 1-hour intravenous
infusion immediately followed by cisplatin 60 mg/m2 in
a 2-hour infusion. Cycles were repeated every 3 weeks if
the patient's blood count had returned to normal and
non-hematologic toxicities had resolved. Dosage of subse-
quent cycles was adjusted according to the observed toxic-
ities that developed during the preceding cycle. The
treatment continued for a maximum of 6 cycles or until
disease progression. All patients received standard sup-
portive care regimen consisting of adequate hydration,
dexamethasone, and antiemetic therapy according to the
guidelines of the American Society of Clinical Oncology
[15].
Statistics
The primary end points of the trial were the efficacy of the
therapy, which were measured as objective response rate
and time to progression, with a secondary end point of
toxicity. All patients who received at least 2 cycles of treat-
ment or who progressed after the first cycle were consid-
ered assessable for response. The study was conducted
using a single-stage, phase II trial design [16]. Based on
the results from previous phase II trials reporting response
rates of about 30% in patients with anthracycline-resistant
MBC, we selected a 50% target response probability and a
30% null response probability, with type I and type II
error set at 10%. The number of patients required was 39.
Statistical calculations were performed using SPSS soft-
ware, version 11.5 (SPSS, Inc, Chicago, IL). Comparisons
were performed using chi-square test and survival curvesBMC Cancer 2005, 5:21 http://www.biomedcentral.com/1471-2407/5/21
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were generated using Kaplan-Meier method. Results were
considered significant at the P = .05.
Results
Patients characteristics
Between Jan 2000 and May 2002, 24 patients with tumors
primary resistant and 15 with secondary resistant disease
were accrued. Among 39 patients assessable for safety, 3
were not evaluable for response due to early discontinua-
tion of treatment.
Baseline characteristics of the eligible patients are listed in
Table 1. Median age was 51 years (range, 41–64) and
median performance status was 1. Thirty-three patients
(85%) had visceral metastases as the dominant site of dis-
ease. All patients had received prior anthracycline-based
chemotherapy with a median number of prior chemo-
therapeutic regimens of 2 (range, 1–3). Three patients
(8%) had exposed to paclitaxel in their previous chemo-
therapy regimen.
Efficacy
According to the "intent-to-treat" analysis, the objective
response rate was 31% (95% confidence interval [CI], 16–
45%). There were 3 complete responses, 12 partial
responses and 15 patients had stable disease. The three
patients who obtained a complete response had non-vis-
ceral metastatic pattern (neck lymph nodes and/or soft tis-
sue lesions). Most patients who achieved a response did
so at the end of the third cycle (median time to response,
2.2 months; 95% CI, 2.1–2.4 months).
At a median follow-up of 40.5 months (95% CI, 36.4–
44.6 months), the median time to progression was 6.6
months (95% CI, 3.9–9.4 months) and the median over-
all survival was 22.9 months (95% CI, 17.2–28.5
months). The time to progression in responders were 16.7
months (P < 0.0001). The Kaplan-Meier method was used
to estimate overall survival and time to progression, as
shown in Figure 1. At the time of present analyses, 21
patients (54%) died.
We observed no significant differences in overall response
rate or survival between primary and secondary anthracy-
cline-resistant groups. The overall survival and time to
progression were higher in patients with objective
response (P < 0.0001 and P = 0.05, respectively).
Toxicity
Patients received a median of 6 cycles (range, 1–6) of
docetaxel plus cisplatin. Relative dose intensities were
84% (95% CI, 73–96%) and 86% (95% CI, 75–97%) for
docetaxel and cisplatin, respectively. Twenty-four patients
(62%) completed 6 cycles of chemotherapy as planned;
Nine patients had progression of disease while receiving
treatment and 6 patients discontinued treatment because
of toxicity. Treatment delay was occurred in 54 cycles
(29%).
Toxicity was evaluable in all 39 patients and 189 chemo-
therapy cycles. Even if the most frequent hematological
toxicity was neutropenia (grade 3/4 in 22% of treatment
cycles), only 12 episodes of non-fatal febrile neutropenia
Table 1: Patient characteristics
No. %
Patients
Treated 39 100.0
Evaluable for response 36 92.3
Age
Median (years) 51.3
Range 41.2 – 64.1
ECOG performance status
03 7 . 7
12 7 6 9 . 2
29 2 3 . 1
Site(s) of metastatic lesion(s)*
Lung 27 69.2
Liver 9 23.1
Lymph node 15 38.5
Soft tissue 3 7.7
Bone 24 61.5
Brain 3 7.7
Response to prior anthracyclines
Primary resistant 24 61.5
Secondary resistant 15 38.5
Interval from the cessation of last chemotherapy
Median (months) 4.1
Range 1.0 – 11.2
No. of prior chemotherapy regimens
Hormonal therapy (total) 20 51.3
19 2 3 . 1
22 1 5 3 . 8
3 or more 9 23.1
Characteristics of prior chemotherapy†
CMF 24
CAF 15
FEC 9
VE 21
High-dose therapy with stem cell rescue 6
AT 3
* Because patients could have metastases at multiple sites, the total 
numbers of metastases are greater than the number of patients.
† CMF, cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, 5-
fluorouracil 600 mg/m2, days 1 & 8, every 4 weeks; CAF, 
cyclophosphamide 500 mg/m2, doxorubicin 50 mg/m2, 5-fluorouracil 
500 mg/m2, every 3 weeks; FEC, 5-fluorouracil 600 mg/m2, epirubicin 
60 mg/m2, cyclophosphamide 600 mg/m2, every 4 weeks; VE, 
vinorelbine 25 mg/m2, days 1 & 8, epirubicin 60 mg/m2 day 1, every 3 
weeks; AT, doxorubicin 50 mg/m2, paclitaxel 175 mg/m2, every 3 
weeks.BMC Cancer 2005, 5:21 http://www.biomedcentral.com/1471-2407/5/21
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were observed. The most commonly encountered non-
hematologic toxicities were asthenia and nausea. Other
toxicities are reported per patient and per cycle in Table 2.
Six patients had severe toxicity precluding further treat-
ment. No treatment-related deaths were observed.
Discussion
Single-agent docetaxel has been considered a standard
treatment for patients with anthracycline-pretreated MBC
for several years. Docetaxel monotherapy often demon-
strated response rates of 50% or more in this setting
[17,18]. Ahn et al. also reported, in a similar patient pop-
ulation, 36% response rate and 69 weeks median survival
with docetaxel 75 mg/m2 every 3 weeks[19].
Platinum-based combinations also have significant activ-
ity in previously treated as well as previously untreated
patients. In several small clinical trials testing the cispla-
tin-based regimens, response rates of 50%-83% were
reported [20]. The North Central Cancer Treatment Group
(NCCTG) evaluated carboplatin combined with paclitaxel
as first-line chemotherapy for MBC [21]. The overall
response rate was 62% and the median time to progres-
sion was 7.3 months. Clearly, platinum-based combina-
tions are very active against MBC, but the relative degree
of toxicity compared with other agents limited their use in
routine clinical practice. Recently, synergism between
platinum and trastuzumab, a novel monoclonal antibody
directed against the protein product of the HER2/neu
oncogene, awaked interest in the use of cisplatin for breast
cancer [6,22].
There are relatively few completed clinical studies involv-
ing platinum-based combination chemotherapy for
anthracycline-resistant MBC. Spielmann et al. evaluated
docetaxel 75 mg/m2  plus cisplatin 80 mg/m2  every 3
weeks in 38 patients with anthracycline-resistant MBC,
giving an objective response rate of 36% [23]. Japanese
investigators performed a phase II study of docetaxel 60
mg/m2 and cisplatin 80 mg/m2 in patients with anthracy-
cline-pretreated MBC [24]. They reported an overall
response rate of 64%. In a phase II study of docetaxel and
carboplatin, overall response rate of 61% was achieved in
patients with chemotherapy-pretreated MBC [25].
Gelmon et al. combined biweekly paclitaxel with cisplatin
and achieved a response rate of 85% with few septic
events [26].
We classified "anthracycline-resistant" into primary and
secondary. Ando et al. suggested that the status of anthra-
cycline-resistance is important for the prediction of
response to second-line treatment with docetaxel [27].
However, we could not observe significant difference in
the efficacy of docetaxel plus cisplatin between primary
and secondary resistant groups. The different outcomes
might be due to the current situation that there have been
no standard criteria defining anthracycline-resistance and
often intermingled with "anthracycline-pretreated" or
"anthracycline-refractory."
This study demonstrated that a combination of docetaxel
plus cisplatin in a 3-week cycle was an effective and well-
tolerated regimen for patients with anthracycline-resistant
MBC. In this study, the use of docetaxel plus cisplatin
resulted in an overall response rate of 31% and the
median time to progression was 7 months. Significant
improvements in the actuarial survival rate and time to
progression were observed in the group of patients who
achieved objective responses. The main toxicities, gas-
trointestinal, hematological and asthenia, were managea-
ble with dose adjustment and supportive care. Dose
intensities of more than 80% were delivered and 61% of
patients completed 6 cycles of chemotherapy, which is
considered acceptable and expected. We used the planned
dose of cisplatin 60 mg/m2 every 3 weeks, rather than 75
mg/m2 cited in a phase I study [14], because we believed
that tolerability of treatment is indispensable in the sal-
vage setting in the management of solid tumors.
With the increasing use of anthracycline-based chemo-
therapy as adjuvant treatment, as well as first-line chemo-
therapy against MBC, patients are frequently exposed to
high cumulative doses of anthracyclines and are therefore
Estimated curves of overall survival and time to progression Figure 1
Estimated curves of overall survival and time to pro-
gression. At a median follow-up of 40.5 months (95% CI, 
36.4–44.6 months), the median time to progression was 6.6 
months (95% CI, 3.9–9.4 months) and the median overall 
survival was 22.9 months (95% CI, 17.2–28.5 months).BMC Cancer 2005, 5:21 http://www.biomedcentral.com/1471-2407/5/21
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at risk of resistance and cardiotoxicity [28]. This combina-
tion of docetaxel with cisplatin may be particularly useful
in patients previously treated with anthracyclines (but
naïve to either docetaxel or cisplatin). In addition, for
patients who have already had cardiac failure and have
not received chemotherapy with taxanes as an adjuvant or
as first-line treatment, use of docetaxel plus cisplatin is
considered a better option. More recently, reports that
trastuzumab has a powerful synergistic interaction with
docetaxel and with cisplatin [29], have prompted evalua-
tion of the combination of trastuzumab with docetaxel
and/or platinum in the treatment of MBC [30,31].
Conclusion
In summary, the combination of docetaxel plus cisplatin
is active and safe in patients with anthracycline-resistant
MBC. The activity observed in anthracycline-resistant and
heavily-pretreated patients suggests relative non-cross-
resistance with other drug combinations. Therefore, we
hope that this study could result in a prospective trial to
determine whether this activity translates into actual
improvement in survival and quality of life in patients
with anthracycline-resistant MBC.
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